108 related articles for article (PubMed ID: 8105301)
1. Monitoring of veno-occlusive disease after bone-marrow transplantation by serum aminopropeptide of type III procollagen.
Salat C; Holler E; Kolb HJ; Hiller E
Lancet; 1993 Oct; 342(8878):1062. PubMed ID: 8105301
[No Abstract] [Full Text] [Related]
2. Monitoring of veno-occlusive disease after bone-marrow transplantation by serum aminopropeptide of type III procollagen.
Yasutomo K; Himeno K
Lancet; 1993 Oct; 342(8878):1062. PubMed ID: 8105302
[No Abstract] [Full Text] [Related]
3. Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen.
Eltumi M; Trivedi P; Hobbs JR; Portmann B; Cheeseman P; Downie C; Risteli J; Risteli L; Mowat AP
Lancet; 1993 Aug; 342(8870):518-21. PubMed ID: 8102667
[TBL] [Abstract][Full Text] [Related]
4. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
[TBL] [Abstract][Full Text] [Related]
5. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation.
Salat C; Holler E; Kolb HJ; Pihusch R; Reinhardt B; Penovici M; Ledderose G; Hiller E
Leuk Lymphoma; 1999 Mar; 33(1-2):25-32. PubMed ID: 10194118
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of procollagen-III peptide as a marker for veno-occlusive disease after bone marrow transplantation.
Schuler U; Subat S; Schmidt H; Schneider A; Ehninger G
Ann Hematol; 1996 Jul; 73(1):25-8. PubMed ID: 8695719
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
Salat C; Holler E; Kolb HJ; Reinhardt B; Pihusch R; Wilmanns W; Hiller E
Blood; 1997 Mar; 89(6):2184-8. PubMed ID: 9058743
[TBL] [Abstract][Full Text] [Related]
8. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
Heikinheimo M; Halila R; Fasth A
Blood; 1994 May; 83(10):3036-40. PubMed ID: 8180401
[TBL] [Abstract][Full Text] [Related]
9. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin.
Rio B; Bauduer F; Arrago JP; Zittoun R
Bone Marrow Transplant; 1993 Jun; 11(6):471-2. PubMed ID: 8334428
[TBL] [Abstract][Full Text] [Related]
10. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation.
Fried MW; Duncan A; Soroka S; Connaghan DG; Farrand A; Peter J; Strauss RM; Boyer TD; McDonald GB
Bone Marrow Transplant; 2001 Mar; 27(6):635-9. PubMed ID: 11319594
[TBL] [Abstract][Full Text] [Related]
11. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
12. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
[TBL] [Abstract][Full Text] [Related]
13. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
[TBL] [Abstract][Full Text] [Related]
14. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
[TBL] [Abstract][Full Text] [Related]
15. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
[TBL] [Abstract][Full Text] [Related]
16. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population.
Sartori MT; Spiezia L; Cesaro S; Messina C; Paris M; Pillon M; Saggiorato G; Pagnan A; Girolami A; Zanesco L; Cella G
Thromb Haemost; 2005 Apr; 93(4):682-9. PubMed ID: 15841312
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
Feldman L; Gabai E; Milovic V; Jaimovich G
Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875
[No Abstract] [Full Text] [Related]
18. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers.
Scrobohaci ML; Drouet L; Monem-Mansi A; Devergie A; Baudin B; D'Agay MF; Gluckman E
Thromb Res; 1991 Sep; 63(5):509-19. PubMed ID: 1755004
[TBL] [Abstract][Full Text] [Related]
19. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
Hägglund H; Ringdén O; Ljungman P; Winiarski J; Ericzon B; Tydén G
Transplant Proc; 1995 Dec; 27(6):3535. PubMed ID: 8540088
[No Abstract] [Full Text] [Related]
20. [Veno-occlusive disease of the liver after bone marrow transplantation. Report of the symposium Autograft in France and the group of study of bone marrow transplantation. France Auto-Greffe et le Groupe d'Etude de la Greffe de Moelle osseuse].
Rio B; Cahn JY; Attal M; Drouet L; Scrobohaci ML; Degos F; Degott C; Bearman SI; Grañena A; Blaise D
Presse Med; 1994 Sep 3-10; 23(26):1217-22. PubMed ID: 7831216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
